Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company’s main growth driver. For 1Q17, ANIK reported that MONOVISC sales grew +24% worldwide vs. 1Q16, with U.S. sales increasing by +26%.
Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company's main growth driver. For 1Q17,...
Anika Therapeutics (ANIK) will receive a US $5MM milestone payment per terms of the MONOVISC® license agreement with U.S. commercial partner, DePuy Mitek. The payment was triggered by $100.0MM in U.S. end-user sales within a consecutive 12-month period at the end of 2Q17.
MONOVISC remains the company’s main growth driver. For 1Q17, ANIK reported that MONOVISC sales grew +24% worldwide vs. 1Q16, with U.S. sales increasing by +26%.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
